Jul 17, 2025
NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy
Jun 16, 2025
NLS Pharmaceutics CEO Issues Letter to Shareholders
May 21, 2025
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
Apr 15, 2025
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models
Feb 27, 2025
NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform
Feb 25, 2025
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
Feb 10, 2025
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies
Jan 31, 2025
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics
Jan 28, 2025
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence
Jan 16, 2025
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS
Dec 30, 2024
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger
Dec 04, 2024
NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market
Jan 28, 2021
NLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering